Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chubb
UBS
Cipla
QuintilesIMS
Moodys

Generated: July 19, 2019

DrugPatentWatch Database Preview

Patent: 7,638,488

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,638,488
Title:Use of alpha-glucosidase inhibitors to treat alphavirus infections
Abstract: The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and at least one additional therapeutic agent.
Inventor(s): Blatt; Lawrence M. (San Francisco, CA), Tan; Hua (Daly City, CA), Seiwert; Scott (Pacifica, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:11/370,535
Patent Claims:see list of patent claims

Details for Patent 7,638,488

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16 ➤ Sign Up Intermune, Inc. (Brisbane, CA) ➤ Sign Up RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16 ➤ Sign Up Intermune, Inc. (Brisbane, CA) ➤ Sign Up RX search
Schering SYLATRON peginterferon alfa-2b VIAL 103949 011 2001-01-19 ➤ Sign Up Intermune, Inc. (Brisbane, CA) ➤ Sign Up RX Orphan search
Schering SYLATRON peginterferon alfa-2b VIAL 103949 010 2001-01-19 ➤ Sign Up Intermune, Inc. (Brisbane, CA) ➤ Sign Up RX Orphan search
Schering SYLATRON peginterferon alfa-2b VIAL 103949 009 2001-01-19 ➤ Sign Up Intermune, Inc. (Brisbane, CA) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Citi
Harvard Business School
Daiichi Sankyo
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.